Rheumatologic and other autoimmune dementias
Laura J. Julian
University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorChristopher M. Filley
University of Colorado School of Medicine, Denver, CO, USA
Denver VA Medical Center, Denver, CO, USA
Search for more papers by this authorLaura J. Julian
University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorChristopher M. Filley
University of Colorado School of Medicine, Denver, CO, USA
Denver VA Medical Center, Denver, CO, USA
Search for more papers by this authorMichael D. Geschwind MD PhD
Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorCaroline Racine Belkoura PhD
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorSummary
Systemic lupus erythematosus (SLE) is the rheumatologic disease whose neuropsychiatric manifestations have received the most attention from both clinicians and researchers. This chapter first focuses on systemic lupus erythematosus and then discusses other rheumatic disorders with the propensity for producing neuropsychiatric sequelae, including the antiphospholipid antibody syndrome (APS), Sjögren's syndrome, the vasculitides, systemic sclerosis (scleroderma), sarcoidosis, and celiac disease. The use of laboratory studies for the diagnosis of rheumatologic conditions has become increasingly refined and remains a key feature of the diagnostic process. Neuropsychological testing in these patients may facilitate the identification of specific patterns of cognitive impairment, assisting patient care and providing clues to pathophysiology. Neurologic complications in many of these diseases are rare, and our knowledge regarding diagnosis, clinical and neuroradiological presentation, and management is largely derived from case reports and case series.
References
- Julian L, Merluzzi NM, Mohr DC. The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis. Mult Scler 2007; 13: 81–86.
- Leritz E, Brandt J, Minor M, Reis-Jensen F, Petri M. “Subcortical” cognitive impairment in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 2000; 6: 821–825.
- Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002; 47: 434–444.
- Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood 2009; 113: 985–994.
- Folstein MF, Folstein SE, McHugh PR. “Mini-mental State.” A practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
- Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778–799.
- Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009; 11: 229.
- Hochberg MC, Perlmutter DL, Medsger TA, et al. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus 1995; 4: 454–456.
- Vilar MJ, Sato EI. Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus 2002; 11: 528–532.
- Jimenez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 2003; 25: 3–12.
- Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999; 11: 352–356.
- Fessler BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Clin North Am 1995; 21: 81–98.
- Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122: 940–950.
- Wong KL, Woo EK, Yu YL, Wong RW. Neurological manifestations of systemic lupus erythematosus: a prospective study. Q J Med 1991; 81: 857–870.
- Kaell AT, Shetty M, Lee BC, Lockshin MD. The diversity of neurologic events in systemic lupus erythematosus. Prospective clinical and computed tomographic classification of 82 events in 71 patients. Arch Neurol 1986; 43: 273–276.
- Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19: 47–52.
- Bluestein HG. Neuropsychiatric disorders in systemic lupus erythematosus. In: RG Lahita, ed. Systemic Lupus Erythematosus. New York: Wiley, 1987, 593–614.
- No author. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.
- Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496–500.
- Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214–1220.
- Kozora E, Ellison MC, West S. Reliability and validity of the proposed American college of rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004; 51: 810–818.
- Brey RL. Neuropsychiatric lupus: clinical and imaging aspects. Bull NYU Hosp Jt Dis 2007; 65: 194–199.
- Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986; 174: 357–364.
- Denburg SD, Carbotte RM, Denburg JA. Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. J Clin Exp Neuropsychol 1987; 9: 323–339.
- Ginsburg KS, Wright EA, Larson MG, et al. A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. Arthritis Rheum 1992; 35: 776–782.
- Glanz BI, Slonim D, Urowitz MB, Gladman DD, Gough J, MacKinnon A. Pattern of neuropsychological dysfunction in inactive systemic lupus erythematosus. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10: 232–238.
- Hanly JG, Fisk JD, Sherwood G, Jones E, Jones JV, Eastwood B. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 1992; 19: 562–567.
- Hay EM, Black D, Huddy A, et al. Psychiatric disorder and cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 1992; 35: 411–416.
- Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996; 39: 2035–2045.
- Wekking EM, Nossent JC, van Dam AP, Swaak AJ. Cognitive and emotional disturbances in systemic lupus erythematosus. Psychother Psychosom 1991; 55: 126–131.
- Loukkola J, Laine M, Ainiala H, et al. Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol 2003; 25: 145–151.
- Hay EM, Huddy A, Black D, et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis 1994; 53: 298–303.
- Kozora E, Arciniegas DB, Filley CM, et al. Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Rheum 2008; 59: 1639–1646.
- Mulherin D, Doherty E, O'Connell A, Bresnihan B. Assessment of cognitive function in patients with systemic lupus erythematosus. Ir J Med Sci 1993; 162: 9–12.
- Appenzeller S, Faria AV, Li LM, Costallat LTL, Cendes F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 2008; 64: 635–643.
- Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998; 41: 41–47.
- Appenzeller S, Bonilha L, Rio PA, Min Li L, Costallat LT, Cendes F. Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. Neuroimage 2007; 34: 694–701.
- Appenzeller S, Rondina JM, Li LM, Costallat LT, Cendes F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2783–2789.
- Brooks WM, Jung RE, Ford CC, Greinel EJ, Sibbitt WL, Jr. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1999; 26: 81–85.
- Kozora E, Arciniegas DB, Filley CM, et al. Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 2005; 18: 159–162.
- Julian L, Katz PP, Trupin L, et al. Cardiovascular disease, cognitive functioning, and depression in SLE: a study using diffusion tensor brain imaging Arthritis Rheum 2009; 60: 1581.
-
Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331–2337.
10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985–992.
- Chapman J, Rand JH, Brey RL, et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003; 12: 514–517.
- Kandiah DA, Sali A, Sheng Y, et al. Current insights into the “antiphospholipid” syndrome: clinical, immunological, and molecular aspects. Adv Immunol 1998; 70: 507–563.
- Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309–1311.
- Mok CC, Lau CS, Wong RW. Neuropsychiatric manifestations and their clinical associations in Southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 766–771.
- Chakravarty KK, Al-Hillawi AH, Byron MA, Durkin CJ. Anticardiolipin antibody associated ischaemic strokes in elderly patients without systemic lupus erythematosus. Age Ageing 1990; 19: 114–118.
- Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.
- Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996; 101: 576–583.
- Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European working party on systemic lupus erythematosus. Medicine (Baltimore) 1993; 72: 113–124.
- Filley CM, Kozora E, Brown MS, et al. White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus. Cogn Behav Neurol 2009; 22: 38–44.
- Denburg SD, Carbotte RM, Denburg JA. Cognition and mood in systemic lupus erythematosus. Evaluation and pathogenesis. Ann N Y Acad Sci 1997; 823: 44–59.
- Leritz E, Brandt J, Minor M, Reis-Jensen F, Petri M. Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. J Clin Exp Neuropsychol 2002; 24: 527–533.
- Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 735–741.
- Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 728–734.
- Whitelaw DA, Spangenberg JJ, Rickman R, Hugo FH, Roberts M. The association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE. Lupus 1999; 8: 444–448.
- Denburg SD, Denburg JA. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus 2003; 12: 883–890.
- Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 1997; 3: 377–386.
- Gomez-Puerta JA, Cervera R, Calvo LM, et al. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology 2005; 44: 95–99.
- Hereng T, Lambert M, Hachulla E, et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 2008; 17: 11–15.
- Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2382–2391.
- Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 56: 2382.
- Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2515–2522.
- Husebye ES, Sthoeger ZM, Dayan M, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1210–1213.
- Sharma A, Isenberg D, Diamond B. Studies of human polyclonal and monoclonal antibodies binding to lupus autoantigens and cross-reactive antigens. Rheumatology (Oxford) 2003; 42: 453–463.
- Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren SI. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12: 392–398.
- Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006; 33: 1553–1558.
- Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-d-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2505–2514.
- DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001; 7: 1189–1193.
- Kowal C, DeGiorgio LA, Nakaoka T, et al. Cognition and immunity: antibody impairs memory. Immunity 2004; 21: 179–188.
- Kozora E, West SG, Maier SF, et al. Antibodies against N-methyl-d-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. J Neurol Sci 2010; 295: 87–91.
- Yoshiyuki A, Tamiko Y, Shunsei H. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 58: 1130–1135.
- Fotini BK, Antonella A, Ales A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54: 312–324.
- Kozora E, Laudenslager M, Lemieux A, West SG. Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J Int Neuropsychol Soc 2001; 7: 745–754.
- Shucard JL, Parrish J, Shucard DW, McCabe DC, Benedict RH, Ambrus J, Jr. Working memory and processing speed deficits in systemic lupus erythematosus as measured by the paced auditory serial addition test. J Int Neuropsychol Soc 2004; 10: 35–45.
- Harle P, Straub RH, Wiest R, et al. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. Ann Rheum Dis 2006; 65: 51–56.
- Bessant R, Duncan R, Ambler G, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum 2006; 55: 892–899.
- Roman MJ, Shanker B-A, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–2406.
- Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407–2415.
- Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48: 3159–3167.
- Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005; 257: 485–495.
- Davis JM, 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 56: 820–830.
- Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 1994; 70: 863–870.
- Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med 1986; 80: 925–929.
- Hughes GRV, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486–489.
- Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KWM, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ; 340: c2541.
- JH Klippel, LJ Crofford, JH Stone, CM Weyand, eds. Primer on the Rheumatic Diseases, 12 ed. Atlanta, Georgia: Arthritis Foundation, 2001.
- Cervera R, Boffa MC, Khamashta MA, Hughes GR. The Euro-phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18: 889–893.
- Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009; 18: 869–874.
- Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 454S–545S.
- Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
- Roldan JF, Brey RL. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 2007; 9: 109–115.
- Erkan D, Kozora E, Lockshin MD. Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome. Pathophysiology 2011; 18: 93–102.
- Liberato B, Levy RA. Antiphospholipid syndrome and cognition. Clin Rev Allergy Immunol 2007; 32: 188–191.
- Appenzeller S, Li LM, Costallat LT, Cendes F. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain 2005; 128: 2933–2940.
- Frances C, Piette JC. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun 2000; 15: 139–143.
- Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore) 1999; 78: 209–219.
- Fetoni V, Grisoli M, Salmaggi A, Carriero R, Girotti F. Clinical and neuroradiological aspects of Sneddon's syndrome and primary antiphospholipid antibody syndrome. A follow-up study. Neurol Sci 2000; 21: 157–164.
- Adair JC, Digre KB, Swanda RM, et al. Sneddon's syndrome: a cause of cognitive decline in young adults. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14: 197–204.
- Geschwind DH, FitzPatrick M, Mischel PS, Cummings JL. Sneddon's syndrome is a thrombotic vasculopathy: neuropathologic and neuroradiologic evidence. Neurology 1995; 45: 557–560.
- Tanne D, Hassin-Baer S. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 2001; 3: 286–292.
- Weissenborn K, Ruckert N, Ehrenheim C, Schellong S, Goetz C, Lubach D. Neuropsychological deficits in patients with Sneddon's syndrome. J Neurol 1996; 243: 357–363.
- Wright RA, Kokmen E. Gradually progressive dementia without discrete cerebrovascular events in a patient with Sneddon's syndrome. Mayo Clin Proc 1999; 74: 57–61.
- Devuyst G, Sindic C, Laterre EC, Brucher JM. Neuropathological findings of a Sneddon's syndrome presenting with dementia not preceded by clinical cerebrovascular events. Stroke 1996; 27: 1008–1010.
- Hannon PM, Kuo SH, Strutt AM, York MK, Kass JS. Improvement of neurological symptoms and memory and emotional status in a case of seronegative Sneddon syndrome with cyclophosphamide. Clin Neurol Neurosurg; 112: 544–547.
- Binard A, Devauchelle-Pensec V, Fautrel B, Jousse S, Youinou P, Saraux A. Epidemiology of Sjogren's syndrome: where are we now? Clin Exp Rheumatol 2007; 25: 1–4.
- Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 2001; 76: 593–599.
- Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in Sjogren's syndrome. Ann Rheum Dis 2004; 63: 616–620.
- Govoni M, Padovan M, Rizzo N, Trotta F. CNS involvement in primary Sjogren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs 2001; 15: 597–607.
- Morgen K, McFarland HF, Pillemer SR. Central nervous system disease in primary Sjögren's syndrome: The role of magnetic resonance imaging. Semin Arthritis Rheum 2004; 34: 623–630.
- Harboe E, Tjensvoll AB, Maroni S, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjogren syndrome: a comparative population-based study. Ann Rheum Dis 2009; 68: 1541–1546.
- Le Guern V, Belin C, Henegar C, et al. Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjogren syndrome: a case-control study. Ann Rheum Dis; 69: 132–137.
- de la Monte SM, Hutchins GM, Gupta PK. Polymorphous meningitis with atypical mononuclear cells in Sjogren's syndrome. Ann Neurol 1983; 14: 455–461.
- Coates T, Slavotinek JP, Rischmueller M, et al. Cerebral white matter lesions in primary Sjogren's syndrome: a controlled study. J Rheumatol 1999; 26: 1301–1305.
- Pierot L, Sauve C, Leger JM, et al. Asymptomatic cerebral involvement in Sjogren's syndrome: MRI findings of 15 cases. Neuroradiology 1993; 35: 378–380.
- Segal BM, Mueller BA, Zhu X, et al. Disruption of brain white matter microstructure in primary Sjogren's syndrome: evidence from diffusion tensor imaging. Rheumatology (Oxford). 2010; 49: 1530–1539.
- Daniels TE, Criswell LA, Shiboski C, et al. An early view of the international Sjogren's syndrome registry. Arthritis Rheum 2009; 61: 711–714.
- Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000; 43: 414–419.
- Hewins PM, Tervaert JWCMDP, Savage COSMDPF, Kallenberg CGMMDP. Is Wegener's granulomatosis an autoimmune disease? [Miscellaneous Article]. Curr Opin Rheumatol 2000; 12: 3–10.
- Eustace JA, Nadasdy T, Choi M. The Churg Strauss syndrome. J Am Soc Nephrol 1999; 10: 2048–2055.
- Joerg S, Sonja K, Juergen S, Stefan F, Angela G, Ulf M-L. Cerebral lesions in patients with connective tissue diseases and systemic vasculitides: are there specific patterns? Ann N Y Acad Sci; 1193: 167–175.
- McKeith IG. Neuropsychiatric symptoms in the course of Wegener's granulomatosis. J Neurol Neurosurg Psychiatry 1985; 48: 713–714.
- Leitch DN, Heald A, Goodship TH. Wegener's granulomatosis: an unusual presentation. Nephrol Dial Transplant 1994; 9: 421–422.
- Mattioli F, Capra R, Rovaris M, et al. Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides. J Neurol Sci 2002; 195: 161–166.
- Jacobi D, Maillot F, Hommet C, et al. P-ANCA cranial pachymeningitis: a case report. Clin Rheumatol 2005; 24: 174–177.
- Horino T, Takao T, Taniguchi Y, Terada Y. Hypertrophic pachymeningitis with MPO-ANCA-positive vasculitis. Clin Rheumatol 2010; 29: 111–113.
- Siva A, Saip S. The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis. J Neurol 2009; 256: 513–529.
- Siva A, Altintas A, Saip S. Behcet's syndrome and the nervous system. Curr Opin Neurol 2004; 17: 347–357.
- Gardner RC, Schmahmann JD. Ataxia and cerebellar atrophy—a novel manifestation of neuro-Behcet disease? Mov Disord 2008; 23: 307–308.
- Matsuo K, Yamada K, Nakajima K, Nakagawa M. Neuro-Behcet disease mimicking brain tumor. AJNR Am J Neuroradiol 2005; 26: 650–653.
- Huang WS, Chiu PY, Kao A, Tsai CH, Lee CC. Decreased cerebral blood flow in neuro-Behcet's syndrome patients with neuropsychiatric manifestations and normal magnetic resonance imaging—a preliminary report. J Neuroimaging 2002; 12: 355–359.
- Harper CM, Jr., O'Neill BP, O'Duffy JD, Forbes GS. Intracranial hypertension in Behcet's disease: demonstration of sinus occlusion with use of digital subtraction angiography. Mayo Clin Proc 1985; 60: 419–422.
- Siva A, Kantarci OH, Saip S, et al. Behcet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001; 248: 95–103.
- Hunder GG. Epidemiology of giant-cell arteritis. Cleve Clin J Med 2002; 69 Suppl 2: SII79–82.
- Fraser JA, Weyand CM, Newman NJ, Biousse V. The treatment of giant cell arteritis. Rev Neurol Dis 2008; 5(3): 140–152.
- Barrier J, Bignon JD, Soulillou JP, Grolleau J. Increased prevalence of HLA-DR4 in giant-cell arteritis. N Engl J Med 1981; 305: 104–105.
- Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285–296.
- Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83: 806–812.
- Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995; 122: 502–507.
- Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998; 41: 1497–1504.
- Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988; 38: 352–359.
- Pascuzzi RM, Roos KL, Davis TE, Jr. Mental status abnormalities in temporal arteritis: a treatable cause of dementia in the elderly. Arthritis Rheum 1989; 32: 1308–1311.
- Small P. Giant cell arteritis presenting as a bilateral stroke. Arthritis Rheum 1984; 27: 819–821.
- Solans-Laque R, Bosch-Gil JA, Molina-Catenario CA, Ortega-Aznar A, Alvarez-Sabin J, Vilardell-Tarres M. Stroke and multi-infarct dementia as presenting symptoms of giant cell arteritis: report of 7 cases and review of the literature. Medicine (Baltimore) 2008; 87: 335–344.
- Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54: 3306–3309.
- Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332–1337.
- Denton CP, Black CM. Targeted therapy comes of age in scleroderma. Trends Immunol 2005; 26: 596–602.
- Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM; 103: 109–115.
- Shah AA, Wigley FM. Often forgotten manifestations of systemic sclerosis. Rheum Dis Clin N Am 2008; 34: 221–238.
- Estey E, Lieberman A, Pinto R, Meltzer M, Ransohoff J. Cerebral arteritis in scleroderma. Stroke 1979; 10: 595–597.
- Giuliodori G, Fraticelli P, Bartolini M, et al. Cognitive and cerebral hemodynamic impairment in scleroderma patients. Eur J Neurol 2009; 16: 1285–1290.
- Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149–173.
- Hosoda Y, Sasagawa S, Yasuda N. Epidemiology of sarcoidosis: new frontiers to explore. Curr Opin Pulm Med 2002; 8: 424–428.
- Rybicki BA, Major M, Popovich J, Jr., Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145: 234–241.
- Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 2001; 248: 363–372.
- Terushkin VBS, Stern BJMD, Judson MAMD, et al. Neurosarcoidosis: presentations and management. Neurologist 2010; 16: 2–15.
- Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3: 397–407.
- Powers WJ, Miller EM. Sarcoidosis mimicking glioma: case report and review of intracranial sarcoid mass lesions. Neurology 1981; 31: 907–910.
- Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Invest 2002; 25: 650–662.
- Hayashi T, Onodera J, Nagata T, Mochizuki H, Itoyama Y. A case of biopsy-proven sarcoid meningoencephalitis presented with hallucination, nominal aphasia and dementia. Rinsho Shinkeigaku 1995; 35: 1008–1011.
- O'Brien GM, Baughman R, Broderick JP. Paranoid psychosis due to neurosarcoidosis. Sarcoidosis 1994; 11: 34–36.
- Bourgeois JA, Maddock RJ, Rogers L, Greco CM, Mangrulkar RS, Saint S. Neurosarcoidosis and delirium. Psychosomatics 2005; 46: 148–150.
- Willigers H, Koehler PJ. Amnesic syndrome caused by neurosarcoidosis. Clin Neurol Neurosurg 1993; 95: 131–135.
- Friedman SH, Gould DJ. Neurosarcoidosis presenting as psychosis and dementia: a case report. Int J Psychiatry Med 2002; 32: 401–403.
- Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis—diagnosis and management. QJM 1999; 92: 103–117.
- Sanders DS, Patel D, Stephenson TJ, et al. A primary care cross-sectional study of undiagnosed adult celiac disease. Eur J Gastroenterol Hepatol 2003; 15: 407–413.
- West J, Logan RF, Hill PG, et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 2003; 52: 960–965.
- Briani C, Zara G, Alaedini A, et al. Neurological complications of celiac disease and autoimmune mechanisms: A prospective study. J Neuroimmunol 2008; 195: 171–175.
- Hadjivassiliou M, Sanders DS, Grünewald RA, Woodroofe N, Boscolo S, Aeschlimann D. Gluten sensitivity: from gut to brain. Lancet Neurol 2010; 9: 318–330.
- Collin P, Pirttila T, Nurmikko T, Somer H, Erila T, Keyrilainen O. Celiac disease, brain atrophy, and dementia. Neurology 1991; 41: 372–375.
- Addolorato G, Giuda DD, Rossi GD, et al. Regional cerebral hypoperfusion in patients with celiac disease. Am J Med 2004; 116: 312–317.
- Hu WT, Murray JA, Greenaway MC, Parisi JE, Josephs KA. Cognitive impairment and celiac disease. Arch Neurol 2006; 63: 1440–1446.
- Hadjivassiliou M, Grunewald RA, Kandler RH, et al. Neuropathy associated with gluten sensitivity. J Neurol Neurosurg Psychiatry 2006; 77: 1262–1266.
- Collin P, Maki M, Kaukinen K. Safe gluten threshold for patients with celiac disease: some patients are more tolerant than others. Am J Clin Nutr 2007; 86: 260; author reply 260-261.
- Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009; 137: 1912–1933.
- Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18: 643–662.
- Golden CJ. Stroop Color and Word Test. Chicago, IL: Stoelting, 1978.
- Trenerry MR, Crosson B, DeBoe J, Leber WR. Stroop Neuropsychological Screening Test. Florida: Psychological Assessment Resources, 1989.
- Dodrill CB. A neuropsychological battery for epilepsy. Epilepsia 1978; 19: 611–623.
- Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, Second ed. New York: Oxford University Press, 1998.
- Army Individual Test Battery: Manual of Directions and Scoring. Washington, DC: War Department, Adjutant General's Office, 1944.
- Wechsler D. Wechsler Adult Intelligence Scale—Third Edition. San Antonio: Psychological Corporation, 1997.
- Delis D, Kramer J, Kaplan E, Ober B. California Verbal Learning Test Manual: Second Edition, Adult Version. San Antonio, TX: Psychological Corporation, 2000.
- Rey A. L'examen clinique in psychologie. Paris: Presses Universitaires de France, 1964.
- Corwin J, Bylsma FW. “Psychological examination of traumatic encephalopathy” by A. Rey and “The Complex Figure Copy Test” by P.A. Osterreith. Clin Neuropsychol 1993; 7: 3–21.
- Spreen O, Benton AL. Neurosensory Center Comprehensive Examination for Aphasia (NCCEA). Victoria: University of Victoria Neuropsychology Laboratory, 1977.
-
Blair JR, Spreen O. Predicting premorbid IQ: a revision of the national adult reading test. Clin Neuropsychol 1989; 3: 129–136.
10.1080/13854048908403285 Google Scholar
- Lezak MD. Neuropsychological assessment (3rd edition). New York: Oxford University Press, 1995.